Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Non-Current Liabilities data on file, last reported at $19.8 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 10.57% year-over-year to $19.8 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 10.57% decrease from a year earlier, with the FY2025 full-year figure at $17.8 million, up 49.58% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $19.8 million, up from $17.8 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PVLA reached as high as $67.6 million in Q4 2022 and fell as low as $10.4 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $25.2 million across 5 years, with a median of $17.8 million in 2025.
• Across the five-year window, Total Non-Current Liabilities tumbled 84.59% in 2023 and jumped 49.58% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $67.6 million in 2022, then tumbled by 84.59% to $10.4 million in 2023, then increased by 14.27% to $11.9 million in 2024, then soared by 49.58% to $17.8 million in 2025, then grew by 11.24% to $19.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $19.8 million in Q1 2026, $17.8 million in Q4 2025, and $16.0 million in Q3 2025.